Erika Bocanegra: Witnessing 25 Years of Progress in Bleeding Disorders Care
Erika Bocanegra, Director of HTC Business Development and Community Engagement at Luskin Orthopaedic Institute for Children, Lifespan Orthopaedic HTC, shared CHES Foundation, Inc.‘s post on LinkedIn:
“When I first started in the bleeding disorders space 25 years ago, many of the treatment options available today were hard to imagine.
Fast forward to today, and we we’ve witnessed incredible advances, from non-factor therapies and extended half-life products to gene therapy and more personalized approaches to care.
It’s been inspiring to watch the field evolve and, more importantly, to see the positive impact these innovations have had on the lives of patients and families.
Excited to see what the future holds!”
CHES Foundation, Inc. shared a post on LinkedIn:
“HYMPAVZI is now approved for people with hemophilia A or B ages 12+ with inhibitors, as well as children ages 6–11 with or without inhibitors.
This milestone also makes HYMPAVZI the first subcutaneous non-factor therapy available for children with hemophilia B ages 6–11.”
Stay updated with Hemostasis Today.
-
Oct 8, 2026, 22:44ISTH 2027 Abstract Submission Opens November 23
-
Oct 8, 2026, 22:41Kunihiro Hattori Pioneering Research for People With Hemophilia A – The Albert and Mary Lasker Foundation
-
Oct 8, 2026, 17:00Sally Mandour: Platelet Size And Shape Can Reveal The Diagnosis
-
Oct 8, 2026, 16:49Neil Morgan: Advancing Understanding Of Bleeding Disorders Of Unknown Cause
-
Oct 8, 2026, 16:38Beverley Hunt: Advancing Pulmonary Embolism Care Through Collaboration And Learning
-
Oct 8, 2026, 16:19Cedric Hermans: Six Webinars Advancing Haemophilia Care And Beyond
-
Oct 8, 2026, 16:09Luana Banu: Every Donation Connects A Human Chain
-
Oct 8, 2026, 15:51Khaled Musallam: A New Era In Thalassemia Care
-
Oct 8, 2026, 15:40Juan J. Ortiz։ Catheter Directed Therapy In Pulmonary Embolism